Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
Friedreich Ataxia · Cardiomyopathy, Secondary
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4
3 insiders sold shares within a month
Since Aug 18, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 26 (planned)
- Started
- Jun 25, 2026
- Main results expected
- Jun 2032
- Fully finished
- Jun 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1: Percent change from baseline in left ventricular mass index by cardiac MRI
Measured over: At Week 26
Cohort 2: Incidence and severity of treatment-emergent adverse events
Measured over: Through Month 60
Cohort 2: Change in clinical routine safety laboratory tests as assessed by standardized clinical laboratory reference ranges
Measured over: Through Month 60
Cohort 2: Change in clinical vital signs (body temperature [°C])
Measured over: Through Month 60
Cohort 2: Change in clinical vital signs (systolic and diastolic blood pressure [mmHg])
Measured over: Through Month 60
Cohort 2: Change in clinical vital signs (heart rate [beats per minute])
Measured over: Through Month 60
Cohort 2: Change in clinical vital signs (respiratory rate [breaths per minute])
Measured over: Through Month 60
Cohort 2: Change in clinical vital signs (oxygen saturation [%])
Measured over: Through Month 60
Cohort 2: Change in clinical 12-lead ECG findings (ECG machine automatically calculates the heart rate [beats per minute] and measures PR, QT, QT interval corrected using Fridericia's method intervals, and QRS complex [milliseconds])
Measured over: Through Month 60
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4, since 2026-08-18, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07721025 · record last updated 2026-09-02 · checked 2026-11-09 15:47 UTC